Cargando…

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib

BACKGROUND: Within the class of tyrosine kinase inhibitors (TKIs), which are used for the treatment of numerous advanced cancers, lenvatinib is associated with a higher prevalence of hypertension (HT) compared with other TKIs. In this study, we investigated the effect of lenvatinib on blood pressure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Kei, Fujii, Hideki, Kono, Keiji, Hirabayashi, Ken, Yamatani, Satoshi, Watanabe, Kentaro, Goto, Shunsuke, Komatsu, Shohei, Fukumoto, Takumi, Nishi, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857786/ https://www.ncbi.nlm.nih.gov/pubmed/33564435 http://dx.doi.org/10.1093/ckj/sfaa137

Ejemplares similares

Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study
por: Yamatani, Satoshi, et al.
Publicado: (2022)

Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis
por: Watanabe, Kentaro, et al.
Publicado: (2020)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus
por: Watanabe, Shuhei, et al.
Publicado: (2020)

Two Cases of Hypophosphatemia with Increased Renal Phosphate Excretion in Legionella Pneumonia
por: Watanabe, Shuhei, et al.
Publicado: (2016)

Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy
por: Okamoto, Kohei, et al.
Publicado: (2021)

Statin Use Influence on the Occurrence of Acute Kidney Injury in Patients with Peripheral Arterial Disease
por: Kanai, Daisuke, et al.
Publicado: (2022)

Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder
por: Watanabe, Kentaro, et al.
Publicado: (2018)

Clinical Implication of Consistently Strict Phosphate Control for Coronary and Valvular Calcification in Incident Patients Undergoing Hemodialysis
por: Shimizu, Mao, et al.
Publicado: (2023)

Clinical value of serum cholinesterase levels in Nephrotic syndrome: an observational study
por: Goto, Kimihiko, et al.
Publicado: (2022)

A Case of Fibrillary Glomerulonephritis with Fibril Deposition in the Arteriolar Wall and a Family History of Renal Disease
por: Watanabe, Kentaro, et al.
Publicado: (2017)

Renal protective effects of astragalus root in rat models of chronic kidney disease
por: Goto, Shunsuke, et al.
Publicado: (2023)

Pregnant Patient on Hemodialysis Who Showed Remarkable Improvement of Severe Hyperparathyroidism by Strict Serum Phosphorus Control
por: Ito, Jun, et al.
Publicado: (2019)

Renin-Angiotensin System Inhibitors Reduce Serum Asymmetric Dimethylarginine Levels and Oxidative Stress in Normotensive Patients with Chronic Kidney Disease
por: Fujii, Hideki, et al.
Publicado: (2014)

Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease
por: Fujii, Hideki, et al.
Publicado: (2012)

Characteristics of coronary artery disease in chronic kidney disease
por: Fujii, Hideki, et al.
Publicado: (2019)

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib
por: Kimura-Tsuchiya, Reiko, et al.
Publicado: (2018)

The Effects of Plasma Exchange on Severe Vasculitis with Diffuse Alveolar Hemorrhage
por: Goto, Kimihiko, et al.
Publicado: (2017)

Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
por: Mizokami, Ken, et al.
Publicado: (2022)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
por: Furuto, Yoshitaka, et al.
Publicado: (2018)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
por: Suzuki, Naomi, et al.
Publicado: (2020)

Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
por: Honda, Shuya, et al.
Publicado: (2019)

Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report
por: Komatsu, Shohei, et al.
Publicado: (2021)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
por: Decraecker, Marie, et al.
Publicado: (2021)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
por: Matsumoto, Yukari, et al.
Publicado: (2022)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Tachiiri, Tetsuya, et al.
Publicado: (2023)

Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma
por: Shiba, Satoshi, et al.
Publicado: (2012)

Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II
por: Izutsu, Takuma, et al.
Publicado: (2020)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
por: Wiegering, Armin, et al.
Publicado: (2014)

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
por: Sukrithan, Vineeth, et al.
Publicado: (2023)

Erratum for Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II
por: Izutsu, Takuma, et al.
Publicado: (2021)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

An Incidental Diagnosis of Microscopic Renal Angiomyolipoma Completely Excised on Renal Biopsy: A Case Report
por: Hyodo, Toshiki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h16jgdim1ua6s91eh6lg7o2k88